VIDEO: CAR-T yields deep, durable response in heavily pretreated multiple myeloma
Click Here to Manage Email Alerts
Ciltacabtagene autoleucel, a BCMA-directed CAR T-cell therapy, yielded an overall response rate of 97% in 97 heavily pretreated patients with relapsed or refractory multiple myeloma, according to data presented at the virtual ASCO Annual Meeting.
Healio spoke with Amrita Y. Krishnan, MD, FACP, director of Judy and Bernard Briskin Multiple Myeloma Center and professor of hematology/hematopoietic cell transplantation at City of Hope Cancer Center, about the median 1-year follow-up data from the phase 1b/2 study, CARTITUDE-1, presented at the meeting.
“This is very exciting in terms of we continue to see these high response rates and the responses do seem to be becoming durable,” Krishnan said.
Krishnan also noted responses seemed to deepen over time and the 12-month PFS was 77%.
Collapse
Usmani SZ, et al. Abstract 8005. Presented at: ASCO Annual Meeting (virtual); June 4-8, 2021.
Click Here to Manage Email Alerts